Hatteras Venture Partners Names Sir Andrew Witty as Chairman

Hatteras Venture Partners has named Sir Andrew Witty as its Chairman and appointed Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, a move the firm describes as an expansion of its proven investment strategies.

The announcement signals a deliberate leadership upgrade at the venture firm, which specializes in life sciences investing. Witty brings decades of senior operating experience in the pharmaceutical industry. Sharpless, a physician, adds scientific and clinical depth to the firm's investment bench.

The appointments place two high-profile figures from the biomedical establishment at the top of Hatteras's leadership structure. The firm frames the hires as a way to scale investment approaches it has already validated, rather than a pivot into new territory.

Witty's role as Chairman will see him guide the firm's overall direction, while Sharpless will lead Hatteras Discovery Innovation, the arm of the business focused on early-stage discovery opportunities.

For a venture firm in the life sciences sector, the caliber of these appointments matters. Early-stage biotech investing depends on scientific judgment as much as financial discipline. A chairman with Witty's industry standing and a managing director with Sharpless's medical credentials strengthen both dimensions.

The structure of the announcement — pairing an industry veteran in the chairman seat with a physician-scientist running discovery — suggests Hatteras intends to deepen its involvement in the earliest, riskiest stages of drug development, where scientific insight determines which companies deserve capital.

The firm's emphasis on "expanding proven investment strategies" indicates continuity. Hatteras is not changing what it invests in; it is adding senior firepower to do more of it.

The appointments come as life sciences venture investing faces a demanding environment, with exit markets tight and fundraising competitive. Firms with deep scientific benches and recognizable leadership have an easier time attracting both limited partners and founding teams.

How quickly Witty and Sharpless translate their operating reputations into deal flow and returns will define whether this leadership expansion marks a genuine scaling of Hatteras's strategy or simply a prestigious reshuffle.